Shares of Horizon Pharma PLC (NASDAQ:HZNP) have been given an average rating of “Buy” by the fifteen brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $18.64.

HZNP has been the subject of several research analyst reports. ValuEngine downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Stifel Nicolaus restated a “buy” rating and set a $20.00 price target on shares of Horizon Pharma in a research report on Sunday, October 22nd. Jefferies Group upped their price target on shares of Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Sunday, September 10th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $17.00 price target on shares of Horizon Pharma in a research report on Monday, September 11th.

Horizon Pharma (NASDAQ HZNP) traded up $0.28 on Thursday, hitting $13.77. 2,689,700 shares of the company traded hands, compared to its average volume of 3,455,445. Horizon Pharma has a 52-week low of $9.45 and a 52-week high of $21.32. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. The firm has a market cap of $2,210.82, a P/E ratio of 9.78, a PEG ratio of 1.14 and a beta of 1.32.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. During the same quarter in the prior year, the firm earned $0.70 EPS. The company’s revenue for the quarter was up 30.1% on a year-over-year basis. sell-side analysts expect that Horizon Pharma will post 0.72 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in HZNP. Bank of Montreal Can raised its holdings in Horizon Pharma by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 1,378 shares during the last quarter. US Bancorp DE raised its holdings in Horizon Pharma by 159.5% in the 2nd quarter. US Bancorp DE now owns 83,165 shares of the biopharmaceutical company’s stock valued at $988,000 after acquiring an additional 51,115 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Horizon Pharma by 82.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after acquiring an additional 69,626 shares during the last quarter. Rothschild Asset Management Inc. raised its holdings in Horizon Pharma by 21.9% in the 2nd quarter. Rothschild Asset Management Inc. now owns 1,476,705 shares of the biopharmaceutical company’s stock valued at $17,528,000 after acquiring an additional 265,013 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in Horizon Pharma by 14.1% in the 2nd quarter. Sei Investments Co. now owns 232,168 shares of the biopharmaceutical company’s stock valued at $2,756,000 after acquiring an additional 28,700 shares during the last quarter. Institutional investors own 86.59% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/horizon-pharma-plc-hznp-given-average-rating-of-buy-by-brokerages/1735495.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.